Industry partnership will determine the success of the transition to low-GWP pMDIs
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However, the success of the transition to new propellants will hinge on partnerships that provide technical expertise alongside regulatory support.
